<DOC>
	<DOCNO>NCT01357759</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , single-dose , dose escalation study healthy male female subject subject Rheumatoid Arthritis ( RA ) determine safety tolerability MORAb-022 .</brief_summary>
	<brief_title>Safety Tolerability MORAb-022 Healthy Rheumatoid Arthritis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion Criteria Rheumatoid Arthritis ( RA ) Subjects : Male female subject age great equal 18 year less equal 75 year . Subjects RA diagnosis per 2010 Rheumatoid Arthritis Classification Criteria per American College Rheumatology ( ACR ) /European League Against Rheumatism ( EULAR . ) BMI le equal 35 kg/m2 Screening . Active RA characterize DAS28 score less equal 5.1 Screening . Have stabilize current dose ( 25 mg/week ) methotrexate ( MTX ) least 4 week randomization . Exclusion Criteria Rheumatoid Arthritis ( RA ) Subjects : Subjects severe active RA stable therapeutic regimen Screening . Subjects without significant articular RA . Relevant history significant respiratory disease ( e.g. , chronic bronchitis , asthma last 5 year , chronic obstructive pulmonary disease , tuberculosis , interstitial lung disease , pneumonitis pulmonary alveolar proteinosis , well significant inhalation exposure silicon substance ) require treatment and/or follow direction physician . Presence GMCSF autoantibodies normal Screening . Abnormal chest xray PFTs judge investigator Screening clinically significant . Positive Quantiferon test . History clinically relevant hypersensitivity reaction ( e.g. , gold therapy ) History medication use might carryover effect study . Previous administration GMCSF modulator within 6 month randomization , previous administration monoclonal antibody immunoglobulin fusion protein ( word `` '' ) GMCSF modulator within 3 month randomization . Use biological therapy test article study ( informed consent termination visit ) Subjects consume great 14 alcoholic drink per week male 7 alcoholic drink per week female . Weight great 120 kg Screening . Use parenteral and/or intraarticular steroid , immunosuppressant , investigational drug , oral anticoagulant drug within 4 week prior randomization . Oral steroid treatment permit dosage less equal 10 mg prednisone daily , stable minimum 4 week study remain unchanged throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>